<DOC>
	<DOCNO>NCT01449357</DOCNO>
	<brief_summary>A Single-arm Phase II Trial Investigating Efficacy Safety Zalutumumab Patients Non-Small Cell Lung Cancer Progressive Disease Treatment Tyrosine Kinase Inhibitors .</brief_summary>
	<brief_title>Zalutumumab Non-Small Cell Lung Cancer ( NSCLC ) Patients Refractory Tyrosine Kinase Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients must document disease progression TKI treatment ( verified CT scan and/or MRI accord RECIST ) . Estimated life expectancy le 3 month . Received follow treatment within 2 week prior Visit 2 : Cytotoxic cytostatic anticancer chemotherapy Total resection irradiation target lesion Any investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Zalutumumab</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
</DOC>